Streetbeat News

Regulatory

GOOG

Alphabet Inc. (GOOG) has demonstrated strong performance in 2024, with its stock gaining approximately 31% despite facing economic and regulatory challenges. The article discusses the potential for GOOG's stock to reach $235 by Q1 2025.

Portfolio Pulse from

November 13, 2024 | 12:15 pm

KXIN

NDAQ

Kaixin Holdings has received a notification from Nasdaq confirming that it has regained compliance with the minimum bid price requirement, as per the decision by the Hearing Panel.

Portfolio Pulse from

November 13, 2024 | 12:15 pm

REGN

Regeneron is set to present its pioneering pipeline progress at the ASH conference, focusing on 10 types of blood cancers and disorders. A key highlight is the oral presentation of head-to-head results for the investigational combination of pozelimab plus cemdisiran versus ravulizumab in treating paroxysmal nocturnal hemoglobinuria.

Portfolio Pulse from

November 13, 2024 | 12:15 pm

GILD

Gilead Sciences presented full results from its Phase 3 PURPOSE 2 trial on lenacapavir, an injectable HIV-1 capsid inhibitor, for HIV prevention. The trial focuses on twice-yearly administration among diverse populations.

Portfolio Pulse from

November 13, 2024 | 12:00 pm

BEN

Levi & Korsinsky is investigating Franklin Resources, Inc. (NYSE:BEN) for potential securities fraud violations. The investigation follows a Wells Notice received by Ken Leech, co-Chief Investment Officer of Franklin's subsidiary, Western Asset Management Company.

Portfolio Pulse from

November 13, 2024 | 11:45 am

SPRY

ARS Pharmaceuticals has launched neffy, an epinephrine nasal spray, in the US and received priority review for a supplemental NDA. They have an exclusive license agreement with ALK-Abelló for commercialization in Europe and Canada, with a potential deal value of $465 million. The company is well-capitalized with $349.6 million in cash.

Portfolio Pulse from

November 13, 2024 | 11:45 am

LQDA

Liquidia Corporation reported its Q3 2024 financial results, highlighting a tentative FDA approval for YUTREPIA™ and a Supreme Court victory regarding patent disputes. The company also raised $100 million in capital.

Portfolio Pulse from

November 13, 2024 | 11:45 am

MSFT

Denmark has introduced a new framework for AI usage under EU regulations, supported by major Danish companies and Microsoft. This framework aims to provide a common standard for AI systems in regulated environments.

Portfolio Pulse from

November 13, 2024 | 11:45 am

XFOR

X4 Pharmaceuticals reported positive Phase 2 study results for mavorixafor in chronic neutropenia and is on track for a Phase 3 trial. The U.S. launch of XOLREMDI® is underway, with a European submission expected by early 2025.

Portfolio Pulse from

November 13, 2024 | 11:30 am

TSLA

Tesla is recalling 2,431 vehicles in the U.S. due to a potential loss of drive power, which could increase the risk of a crash, according to the U.S. National Highway Traffic Safety Administration.

Portfolio Pulse from

November 13, 2024 | 11:30 am